Animal Models for Evaluation of Antifungal Efficacy Against Filamentous Fungi

Medical Mycology: Cellular and Molecular Techniques

Volumn , Issue , 2007, Pages 115-135

  Dannaoui, Eric ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Antifungal efficacy evaluation animal models; Disseminated aspergillosis in neutropoenic mice; Disseminated zygomycosis in non immunosuppressed mice; in vitro antifungal susceptibility testing; Organ fungal burden studies; Quantitative PCR methods and PCR amplification

Indexed keywords

EID: 45049088509     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470057414.ch6     Document Type: Chapter

References (39)

1. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong et al. (1997) Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 41: 2333-2338.
2. Andes, D. (2005) Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy. Methods Mol Med 118: 111-128.
3. Bowman, J. C., Abruzzo, G. K., Anderson, J.W., Flattery, A. M. et al. (2001) Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. 45: 3474-3481.
4. Cacciapuoti, A., Loebenberg, D., Corcoran, E., Menzel, F. Jr. et al. (2000) In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. 44: 2017-2022.
5. Clemons, K. V. and Stevens, D. A. (2005) The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. Med. Mycol. 43 Suppl 1: S101-110.
6. CLSI (2002) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard. Document M-38A, Clinical and Laboratory Standards Institute, Wayne, Pa.
7. Dannaoui, E., Borel, E., Monier, M. F., Piens, M. A. et al. (2001) Acquired itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 47: 333-340.
8. Dannaoui, E., E. Borel, F. Persat, M. F. Monier and M. A. Piens (1999) In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. J. Med. Microbiol. 48: 1087-1093.
9. Dannaoui, E., O. Lortholary and F. Dromer (2004) In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob. Agents Chemother. 48: 970-978.
10. Dannaoui, E., J. F. Meis, D. Loebenberg and P. E. Verweij (2003) Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother. 47: 3647-36450.
11. Dannaoui, E., Mouton, J.W., Meis, J. F. and Verweij, P. E. (2002) Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. Antimicrob. Agents Chemother. 46: 1953-1959.
12. Denning, D. W., Venkateswarlu, K., Oakley, K. L., Anderson, M. J. et al (1997) Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 41: 1364-1368.
13. Graybill, J. R. (2000) The role of murine models in the development of antifungal therapy for systemic mycoses. Drug Resist. Update. 3: 364-383.
14. Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E.R., et al. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347: 408-415.
15. Husain, S., Alexander, B. D., Munoz, P., Avery, R. K. et al. (2003) Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin. Infect. Dis. 37: 221-229.
16. Ibrahim, A. S., Avanessian, V., Spellberg B. and Edwards, J. E. Jr. (2003) Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob. Agents Chemother. 47: 3343-3344.
17. Ibrahim, A. S., Bowman, J. C., Avanessian, V., Brown, K. et al. (2005) Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob. Agents Chemother. 49: 721-727.
18. Johnson, E. M., Oakley, K. L., Radford, S. A., Moore, C. B. et al. (2000) Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J. Antimicrob. Chemother. 45: 85-93.
19. Kamei, K. (2001) Animal models of zygomycosis-Absidia, Rhizopus, Rhizomucor, and Cunninghamella. Mycopathologia. 152: 5-13.
20. Keating, G. M. and Jarvis, B. (2001) Caspofungin. Drugs 61: 1121-1129.
21. Kirkpatrick, W. R., Perea, S., Coco, B. J. and Patterson, T. F. (2002) Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46: 2564-2568.
22. Kontoyiannis, D. P., Lionakis, M. S., Lewis, R. E., Chamilos, G. et al. (2005) Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 191: 1350-1360.
23. Latge, J. P. (1999) Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12: 310-350.
24. Lewis, R. E. andWiederhold, N. P. (2005) Murine model of invasive aspergillosis. Methods Mol. Med. 118: 129-142.
25. Lozano-Chiu, M., Arikan, S., Paetznick, V. L. Anaissie, E. J. et al. (1999) Treatment of murine fusariosis with SCH 56592. Antimicrob. Agents Chemother. 43: 589-591.
26. Marr, K. A., Carter, R. A., Crippa, F.,Wald, A. and Corey, L. (2002) Epidemiology and outcome of mould infections in haematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34: 909-917.
27. Mosquera, J., Warn, P. A., Rodriguez-Tudela, J. L. and Denning, D. W. (2001) Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole. J. Antimicrob. Chemother. 48: 583-586.
28. Murphy, M., Bernard, E. M., Ishimaru, T. and D. Armstrong (1997) Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41: 696-698.
29. Odds, F. C., Van Gerven, F. Espinel-Ingroff, A., Bartlett, M. S. et al. (1998) Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob. Agents Chemother. 42: 282-288.
30. Padhye, A. A. and Ajello, L. (1988) Simple method of inducing sporulation by Apophysomyces elegans and Saksenaea vasiformis. J. Clin. Microbiol. 26: 1861-1863.
31. Perfect, J. R., Cox, G. M., Dodge, R. K. and Schell,W. A. (1996) In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 40: 1910-1913.
32. Petraitiene, R., Petraitis, V. Groll, A. H., Sein, T. et al. (2001) Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob. Agents Chemother. 45: 857-869.
33. Polak, A. (1999) The past, present and future of antimycotic combination therapy. Mycoses. 42: 355-370.
34. Rex, J. H., Nelson, P. W., Paetznick, V. L., Lozano-Chiu, M. et al. (1998) Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 42: 129-134.
35. Spellberg, B., Fu, Y., Edwards, J. E. Jr. and Ibrahim, A. S. (2005) Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob. Agents Chemother. 49: 830-832.
36. Steinbach, W. J., Stevens, D. A. and Denning, D. W. (2003) Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin. Infect. Dis. 37 (Suppl 3): S188-224.
37. Stevens, D. A., Kan, V. L., Judson, M. A., Morrison, V. A. et al. (2000) Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin. Infect. Dis. 30: 696-709.
38. Sun, Q. N., Najvar, L. K., Bocanegra, R., Loebenberg, D. and Graybill, J. R. (2002) In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob. Agents Chemother. 46: 2310-2312.
39. Vitale, R. G., Afeltra, J. and Dannaoui, E. (2005) Antifungal Combinations. Methods Mol. Med. 118: 143-152.